| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5698226 (Pediatric) | GLAXOSMITHKLINE LLC | Water-dispersible tablets |
Jul, 2012
(11 years ago) | |
Lamictal Cd is owned by Glaxosmithkline Llc.
Lamictal Cd contains Lamotrigine.
Lamictal Cd has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Lamictal Cd are:
- US5698226*PED
Lamictal Cd was authorised for market use on 08 September, 2000.
Lamictal Cd is available in tablet, for suspension;oral dosage forms.
The generics of Lamictal Cd are possible to be released after 18 May, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | May 18, 2018 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 08 September, 2000
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
How can I launch a generic of LAMICTAL CD before it's drug patent expiration?
More Information on Dosage
LAMICTAL CD family patents
